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Abstract
Common gastrointestinal diseases such as radiation 
enteritis (RE), acute pancreatitis, inflammatory bowel 
diseases (IBD) and drug-induced hepatotoxicity share 
pathophysiological mechanisms at the molecular level, 
mostly involving the activation of many pathways of 
the immune response, ultimately leading to tissue in-
jury. Increased oxidative stress, inflammatory cytokine 
release, inflammatory cell infiltration and activation and 
the up-regulation of inflammatory transcription factors 
participate in the pathophysiology of these complex 
entities. Treatment varies in each specific disease, but 
at least in the cases of RE and IBD immunosuppressors 
are effective. However, full therapeutic responses are 
not always achieved. The pathophysiology of ischemia-
reperfusion (IR) injury shares many of these mecha-
nisms. Brief and repetitive periods of ischemia in an 
organ or limb have been shown to protect against sub-
sequent major IR injury in distant organs, a phenome-
non called remote ischemic preconditioning (RIP). This 
procedure has been shown to protect the gut, pancreas 
and liver by modulating many of the same inflamma-
tory mechanisms. Since RIP is safe and tolerable, and 
has shown to be effective in some recent clinical trials, 
I suggest that RIP could be used as a physiologically 
relevant adjunct treatment for non-ischemic gastroin-
testinal inflammatory conditions.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Ischemia-reperfusioin injury, which commonly 
occurs during transplant procedures, is associated with 
inflammatory cytokine release, endothelial dysfunction 
and oxidative stress. Remote ischemic-preconditioning 
is a procedure that can attenuate all of these altera-
tions. The pathophysiology of many non-ischemic gas-
trointestinal disorders, such as radiation-induced en-
teritis and inflammatory bowel disease, among others, 
involves many of these same mechanisms. Future re-
search should address the question of whether remote 
ischemic-preconditioning could also favorably alter the 
course of these diseases.
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INTRODUCTION
Ischemia-reperfusion (IR) injury occurs when blood 
flow to an organ is interrupted, such as in arterial em-
bolism or thrombosis, during transplant procedures or 
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shock, followed by restoration of  blood flow[1,2]. The 
initial injury (ischemia) causes depletion of  tissue energy 
resources, activation of  proteases and increased calcium 
influx into ischemic cells, and reperfusion exacerbates the 
extent of  injury through the stimulation of  an intense 
systemic inflammatory response. This leads to tissue 
microcirculatory failure, necrosis and apoptosis. Marked 
pro-inflammatory cytokine release, inflammatory cell in-
filtration, production of  reactive oxygen species (ROS), 
increased expression of  nitric oxide (NO), Toll-like re-
ceptor (TLR)-4 signaling and activation of  inflammatory 
transcription factors, among other complex pathways, 
are centrally involved in the events leading to IR-injury 
in various organs[2-4]. The gut and the liver are among the 
most ischemia-sensitive tissues.
Treatments aimed at attenuating IR-injury often in-
volve the inhibition of  one or many of  these inflamma-
tory pathways. Experimental success has been achieved 
with single cytokine blockers as well as with pleiotropic 
compounds with various immunomodulatory effects in 
both intestinal and liver IR-injury[5,6]. Recently, another 
strategy has proven useful in reducing IR-injury, ischemic 
preconditioning (IP). IP consists of  a brief  episode of  
ischemia that precedes the major ischemic event, and 
leads to the modulation of  the innate organ defenses 
and inflammatory response, leading to decreased result-
ing injury[7]. The molecular mechanisms of  IP are com-
plex, and involve various pathways. IP leads to increased 
natural antioxidants such as glutathione, superoxide dis-
mutase, heme-oxygenase-1 (HO-1), and reduced levels of  
lipid peroxidation[8]. Nuclear transcription factors such as 
nuclear factor-kappaB (NF-KappaB) are also regulated 
by IP, leading to reduced pro-inflammatory cytokines 
production and release[7]. Additionally, NO production is 
modulated by IP, leading to preserved sinusoidal blood 
flow, oxygenation and mitochondrial function[8]. These 
events prepare tissues to withstand IR injury, with im-
pressive efficacy.
Remote ischemic-preconditioning (RIP) has emerged 
as an interesting alternative to direct IP. RIP involves the 
induction of  protection against IR injury in an organ by 
brief  episodes of  ischemia and reperfusion in an entirely 
different organ or limb[9]. These protective effects begin 
few hours after preconditioning and may persist for up 
to 72 h. Circulating mediators and/or signals are hy-
pothesized to mediate this effect, and some mechanisms 
involved so far are similar to those that applied in direct 
IP, including modulation of  inflammatory cells, cytokines 
and oxidative stress[9,10].
Specific mechanisms involved in RIP-induced protec-
tion are also being uncovered. The induction of  intestinal 
or hepatic RIP was shown to protect against subsequent 
renal IR by the attenuation of  oxidative stress, lipid per-
oxidation, cytokine release, NO production and the up-
regulation of  endogenous antioxidant mechanisms[11,12], 
and further studies have established that NO is an im-
portant mediator of  RIP as well[13,14]. RIP normalizes 
NO production in mitochondria, and attenuates oxida-
tive stress-mediated mitochondrial injury (24). HO-1, 
heat shock proteins (hsp), antioxidant and cytoprotective 
defense systems, are also upregulated by RIP and also at-
tenuate tissue injury[9,10,15].
RIP also leads to reduced levels of  tumor necrosis 
factor alpha (TNF-α) and inhibits crosstalk between 
TNF-α receptors and the induction of  NF-KappaB[9,10,16]. 
RIP leads to reduced production and release of  other 
proinflammatory cytokines and suppression of  NF-
KappaB-induced inflammation, and RIP has been shown 
to reduce long term transforming growth factor-beta 
(TGF-β) expression and fibrosis in kidneys damaged by 
IR injury[17,18]. Signal transduction and activator of  tran-
scription (STAT) pathways have also been involved in the 
pathophysiology of  IR injury, and RIP is known to mod-
ulate STAT activity, leading to regulation of  inflammation 
and cell survival[19,20]. Rats that are deficient in TLR-4 do 
not show RIP liver protection, suggesting a role for TLRs 
in the induction of  preconditioning-associated ischemic 
tolerance[21,22].
In experimental studies, both IP and RIP have been 
shown to be beneficial in IR-injury of  the gut, liver and 
pancreas[23-25]. The traditional view is that both IP and 
RIP protect tissues from a subsequent episode of  full 
blown IR-injury. However, the variety of  the inflamma-
tory pathways regulated by these interventions suggests 
that they have wide-ranging immunomodulatory proper-
ties (Figure 1). Experimental studies have shown that IP 
and RIP are able to attenuate the inflammatory response 
and the severity of  injury in various animal models of  
non-ischemic insults such as lipopolysaccharide-induced 
sepsis[26], traumatic brain injury[27] and cerulein-induced 
pancreatitis[28]. An interesting question that arises is 
whether these properties could be beneficial in non-isch-
emic but inflammatory conditions of  the gastrointestinal 
system. 
In this review, I propose that given the similarity in 
the physiopathology of  IR-injury, RIP-induced protec-
tion and some gastrointestinal inflammatory conditions, 
RIP could show beneficial effects in their clinical course. 
That is, the idea of  RIP as a general “immunomodula-
tory” strategy, outside of  its application solely to limit 
IR-injury. I focus on drug-induced hepatotoxicity, inflam-
matory bowel diseases (IBD), radiation enteritis (RE) and 
acute pancreatitis (AP). Although it is outside the scope 
of  this paper to review in detail the pathophysiology of  
these diseases, in the following sections I discuss relevant 
evidence in support for the current proposal.
HUMAN STUDIES OF REMOTE ISCHEMIC 
PRECONDITIONING
RIP is less invasive than IP and has led to great clinical 
interest for its application[10]. RIP is safe, tolerable, with 
no clear side effects, and has been used effectively in 
several clinical trials[29]. The induction of  forearm or leg 
IR by the inflation of  a blood-pressure cuff  for brief  
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episodes (5 min) is the preferred method in human trials, 
that has shown promising results in the setting of  myo-
cardial ischemia[10]. The possibility of  using it on mul-
tiple occasions or intermittently remains open. A recent 
meta-analysis of  23 clinical trials including 1878 patients 
undergoing RIP, mostly for cardiac surgery, was recently 
published[30]. Although it found no mortality benefit, it 
did find reduced levels of  myocardial infarction and con-
firmed the procedure’s safety. RIP has no known interac-
tion with drug treatment, so it could be safely used as an 
adjunct to standard therapy. A recent small randomized 
controlled trial showed that arm RIP provided protection 
against contrast-medium induced nephrotoxicity[31]. This 
is the first clinical example of  a study that used RIP with 
the aim of  providing protection against a non-ischemic 
insult (contrast nephropathy).
RIP is associated with few side effects apart from 
slight discomfort, and published protocols can be easily 
replicated. One of  the most common protocols involves 
performing 4 cycles of  alternating 5-min inflation and 
5-min deflation of  a standard upper-arm blood pressure 
cuff  to the individual’s systolic blood pressure plus 50 
mmHg to induce transient and repetitive arm ischemia 
and reperfusion[31]. Number of  cycles, ischemia time, and 
selected limb (arm or leg) can vary.
DRUG-INDUCED HEPATOTOXICITY
Drug induced acute liver failure (ALF) is one of  the most 
severe and feared adverse reactions associated with drugs. 
Drug induced hepatotoxicity in general population has 
been estimated to be around 14/100000 inhabitants in 
Western countries, and contributes to 10%-50% of  all 
causes of  ALF[32]. Acetaminophen (ACP) intoxication, 
either accidental or intentional, is by far the most com-
mon, due to the universal access to this analgesic, and has 
a mortality rate of  32%-50%[32]. The specific treatment 
consist of  n-acetylcysteine administration, an antioxidant 
that also affects ACP metabolism[33]. However, it requires 
complex dosing regimens, and the search for alternative 
therapeutic strategies is an active field of  research.
The pathophysiology of  ACP induced hepatotoxicity 
is well understood. ACP is metabolized by cytochrome 
P450 into N-acetyl-p-benzoquinone imine (NAPQI), a 
toxic metabolite, which is then conjugated to glutathi-
one and detoxified under physiologic circumstances to 
mercapturic acid[34]. With ACP overdose, glutathione is 
depleted and excess NAPQI binds to intracellular pro-
teins causing mitochondrial dysfunction and permeability, 
leading to increased oxidative stress and the induction of  
a sterile inflammatory response[35]. Hepatocytes, Kupffer 
cells, and other circulating non parenchymal cells resi-
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Figure 1  Pathophysiology of ischemia-reperfusioin injury and mechanisms modulated by remote ischemic preconditioning. There are multiple pathways 
involved in the pathophysiology of ischemia-reperfusion (IR) injury. This leads to end organ damage as discussed in the text. Inflammatory cell infiltration and activa-
tion during IR is driven by multiple signaling pathways and lead to tissue inflammation. (1) Remote ischemic preconditioning (RIP) can modulate inflammatory cell 
infiltration and activity. Inflammatory cells and resident cells produce inflammatory cytokines and chemokines, partly in response to signal transducers and activators 
of transcription factor (STAT) and nuclear factor kappa B (NF-Kappa B) signaling; (2) RIP can reduce cytokine and chemokine production and modulate STAT activ-
ity. Local and infiltrating inflammatory cells produce reactive oxygen species (ROS) that deplete endogenous antioxidants (EA), resulting in tissue distruction; (3) RIP 
reduces production of ROS and increases levels of EA. During IR, heme-oxygenase-1 (HO-1) and heat shock proteins (hsp) are upregulated, Toll-like receptors (TLRs) 
are activated and mitochondrial function is disrupted; (4) RIP modulates TLR signaling, protects mitochondria and regulates HO-1 production. All of these events lead 
to microcirculatory failure and finally cellular apoptosis; and (5) RIP preserves microcirculation and reduces pro-apoptotic signals. ATP: Adenosine triphosphate.
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INFLAMMATORY BOWEL DISEASE
IBD encompass a wide variety of  conditions, of  which 
ulcerative colitis and Crohn’s disease are the best under-
stood. Their combined incidence and prevalence is ap-
proximately 5 cases per 100000 and 100 cases per 100000 
population, respectively[43]. They constitute chronic 
inflammatory disorders of  the gastrointestinal tract that 
share clinical and pathophysiological similarities, and can 
present with diarrhea, bloody stools, abdominal pain, 
weight loss and systemic signs of  inflammation (depend-
ing on specific disease type). Alterations in innate im-
munity and in resident and infiltrating inflammatory cells 
such as neutrophils, CD4 lymphocytes, macrophages 
and mast cells lead to increased production of  inflam-
matory cytokines of  both the Th1 and Th2 response are 
the main effectors in these diseases[44]. Although initiator 
cytokines such as interleukin (IL)-17 and IL-13 dominate 
the initial response, the downstream mediators IL-1, IL-6 
and TNF-α are the central regulators of  tissue damage in 
IBD[45]. Besides immunosuppressive therapy, TNF-α an-
tagonist therapy has shown tremendous effectiveness in 
the management of  IBD. However, definitive treatment 
only exists in the form of  surgery (in some cases), and 
disease can progress even under optimal pharmacologic 
therapy.
It is known that RIP is effective in reducing intestinal 
IR injury[23], and I have previously reviewed evidence that 
suggests RIP can modulate inflammatory cytokine pro-
duction, including robust effects over TNF-α. Intestinal 
IP in particular has been shown to reduce the mRNA 
levels of  many pro-inflammatory cytokines, including 
TNF-α and IL-1[46].
STAT proteins participate in cytokine-induced T-cell 
activation in IBD, and activation of  STAT-4 and STAT-3 
in T cells is an essential step in the physiopathology of  
Crohn’s disease[47]. The transcription factor NF-kappaB ac-
tively participates in the excessive inflammatory response 
observed in IBD, using TLR pathways, both in intestinal 
mucosal and inflammatory cells[48]. As I discussed, RIP is 
also able to modulate both of  these transcription factors. 
Additionally, during IBD, endothelial cells are modified 
by intestinal inflammation, leading to altered responses 
to leukocyte-cell interactions and inflammatory cytokines, 
contributing to the initiation and propagation of  IBD-
related pathology[49]. RIP is known to protect endothelial 
cells from various insults. Intestinal IP can directly reduce 
NF-KappaB activation after IR-injury[46], and can also 
modulate leukocyte-endothelial interactions[50].
Recent evidence has shown that in response to in-
flammatory cytokine production, ROS are produced 
during disease activity in IBD, and that oxidative stress 
could be a triggering factor, rather than a concomitant 
occurrence during the pathogenesis of  these diseases[51]. 
Not only are oxidants overproduced but antioxidants also 
are overexpressed as a natural defense mechanism against 
oxidative injury during IBD activity[52]. HO-1 is also a 
main endogenous defense mechanism against intestinal 
dent synthesized other pro-inflammatory and injurious 
substances in response to these events. Among these, 
NO has been shown to play a major role in controlling 
lipid peroxidation and oxidative stress[36,37]. Induction of  
proteins that act as natural antioxidant defenses, such as 
HO-1 and heat shock protein 70 (hsp70), are increased 
by ACP in hepatocytes[38,39] in an attempt to reduce oxi-
dative stress injury. Pro-inflammatory cytokines such as 
TNF-α are produced and other mediators such as TLR-4 
are activated by ACP intoxication and are responsible for 
further damage and the perpetuation of  the inflamma-
tory response[40,41].
All of  these pathways have been shown to be modu-
lated by RIP in the liver. In a rodent model of  hindlimb 
RIP, RIP led to the suppression of  pro-inflammatory 
genes and the expression of  antioxidant genes, leading 
to increased levels of  glutathione, HO-1 and reduced 
TNF-α release in hepatocytes[22,24]. NO induced in the 
liver by RIP leads to preservation of  the sinusoidal struc-
ture and maintenance of  blood flow through the hepatic 
microcirculation, as well as improved mitochondrial oxy-
genation and reduced acidosis[4,42]. Finally, TLR-4 knock-
out mice have failed to induce hepatoprotection in RIP, 
suggesting a role for TLR-4 as well[22]. 
The overlap between the mechanisms responsible for 
ACP hepatotoxicity and those of  RIP is striking (Table 1). 
Hypothetically, upon receiving a patient with suspected 
ACP intoxication, besides conventional treatment, fore-
arm RIP could be initiated, which would hypothetically 
lead to reduced pro-inflammatory mediators production 
and increased antioxidant defense in the liver. This could 
partially mitigate the hepatotoxic effects of  ACP, a com-
mon entity with high morbidity and mortality. Thus RIP 
could function as a physiologically reasonable adjunct 
treatment for ACP intoxication. 
  Some mechanisms of ACP-induced
  hepatotoxicity, RE, IBD and AP
Effects of RIP
  Inflammatory cytokine production Reduced inflammatory cytokines
  Increased oxidative stress Inhibits oxidative stress
  Depletion of glutathione Increased glutathione synthesis
  NO expression and release Modulation of NO function
  iNOS expression Modulation of iNOS
  HO-1 and hsp70 production Promotes HO-1 and hsp70 production
  TLR signaling Modulates TLR signaling
  Th1 and Th2 cytokine imbalance Reduced inflammatory cytokines 
  STAT and NF-kappaB signaling Modulation of STAT and NF-KappaB
  TGF-β production Regulation of TGF-β production
Table 1  Pathways participating in the physiopathology of 
some gastrointestinal diseases and effects of remote ischemic 
preconditioning
Note: Adapted from text. ACP: Acetaminophen; RE: Radiation-induced 
enteritis; IBD: Inflammatory bowel disease; AP: Acute pancreatitis; RIP: 
Remote ischemic preconditioning; HO-1: Heme oxygenase-1; hsp70: 
Heat shock protein-70; TLR: Toll-like receptor; NO: Nitric oxide; iNOS: 
Inducible nitric oxide synthase; STAT: Signal transduction and activator 
of transcription; NF-kappaB: Nuclear factor-kappaB; TGF-β: Transforming 
growth factor-beta.
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inflammation that has been hypothesized to participate 
in the pathophysiology of  IBD[53]. Experimental studies 
have also established a protective role for Hsp70 against 
colitis trough suppression of  inflammatory cytokines and 
apoptosis[54]. Constitutive and inducible NO synthetase 
(iNOs) participates in the initiation and regulation of  
inflammation during IBD[55], and has complex immune-
modulating effects in normal intestinal homeostasis. Of  
course, RIP is associated with antioxidant effects, HO-1 
and Hsp70 expression and modulation of  NO responses. 
In rat models of  intestinal IR, both IP and RIP were able 
to increase serum levels of  HO-1 conferring cytoprotec-
tion[23,50], and RIP has been shown to modulate NO pro-
duction and decrease lipid peroxidation in the colon[56]. 
Intestinal inflammatory diseases such as IBD also 
share many pathophysiological mechanisms with IR in-
jury (Table 1), and there is direct experimental evidence 
suggesting that the mediators discussed above are capable 
of  being regulated by RIP in intestinal tissues, making 
IBD another important candidate for RIP therapy. Of  
course, the ideal phase of  intervention would be an acute 
flare of  IBD, since these conditions have clear chronic 
courses. Some form of  “pulse” therapy or periprocedural 
(in endoscopic procedures) use of  RIP could also be 
promising.
RADIATION-INDUCED ENTERITIS
Radiotherapy for pelvic and abdominal tumors causes 
severe gastrointestinal complications. The intestines are 
very sensitive to radiation injury and they constitute a 
dose-limiting organ. As many as 16% of  patients receiv-
ing abdominal or pelvic radiotherapy will develop chronic 
RE, and even more will suffer from the acute phase of  
this entity[57]. Acute symptoms include diarrhea, nausea 
and vomiting, and chronic manifestations include stric-
ture formation, obstruction, inflammation, bleeding and 
fibrosis. Both phases of  RE are thought to occur due to 
an imbalance of  inflammatory and anti-inflammatory 
mediators. There is scarce evidence favoring an effective 
therapeutic regimen for RE, and the search for novel 
treatment or preventive strategies is ongoing[58]
Experimental evidence points towards an important 
role for oxidative stress in the physiopathology of  RE. 
After radiation exposure, there is an important imbal-
ance in the oxidative status of  the intestine[59]. Increased 
myeloperoxidase, malonaldehide and decreased levels 
of  glutathione have been associated with the acute 
inflammatory phase of  RE[60]. RE also induces HO-1 
expression, and the over-expression of  HO-1 leads to 
tissue protection in acute RE[61]. The administration of  
antioxidants, like vitamin-E, diminish experimental RE 
by decreasing lipid peroxidation and increasing glutathi-
one levels in the gut[62,63]. Increased induction of  iNOS 
has also been observed in the colon after acute RE, and 
iNOS inhibitors diminish some of  the alterations associ-
ated to RE[64,57].
The coordinated activity of  several adhesion mol-
ecules participate in the recruitment of  leukocytes into 
inflamed tissue in the setting of  RE[65]. RE also induces 
the expression of  adhesion molecules and other inflam-
matory mediators, such as cytokines and chemokines, 
both locally and systemically[66]. There are many lines of  
evidence that implicate cytokine imbalances directly in 
the pathogenesis of  RE. In a rodent model of  RE, the 
ileal expression of  IL-1, IL-6, TNF-α, TGF-β was mark-
edly increased, while the levels of  the anti-inflammatory 
cytokine IL-10 were found to be diminished, all in as-
sociation with activation of  NF-KappaB[67]. NF-KappaB 
inhibition, in turn, was able to diminish the severity of  
RE, as well as the associated inflammatory response[68]. 
The shift towards a Th-2 like response, with release of  
inflammatory cytokines IL-1 and TNF-α, was shown to 
persist for up to 6 mo after RE, suggesting a role for this 
mechanisms in the chronic phase as well[64]. This same 
study also showed the induction of  the IL-10/STAT 
3 pathway by RE. At least one study has confirmed el-
evated levels of  inflammatory cytokines in the mucosa of  
patients with radiation-induced proctitis[69].
The chronic phase of  RE, characterized by fibrosis, 
is also associated to an inflammatory response. In ro-
dent models, TGF-β immunoreactivity was found to be 
increased in the intestines after RE and to correlate well 
with both acute and chronic histopathologic lesions[70]. 
TGF-β and its pathways are central mediators of  fibro-
genesis and currently constitute an important therapeutic 
target for RE[71]. In experimental studies, IP could reduce 
the chronic elevations of  TGF-β after renal IR-injury[17], 
but these results have not been replicated in models of  
liver IR[72].
RE constitutes another pathology that shares many 
pathophysiological mechanisms with IR-injury (Table 1). 
It is therefore unsurprising that many of  these mecha-
nism are affected by RIP as well, including regulation of  
cytokine balance, attenuation of  oxidative stress and the 
modulation of  transcription factors such as NF-KappaB. 
There is another important aspect to RE which makes it 
ideal for intervention with RIP: the fact that it is an ex-
pected complication, a side effect. This allows for the use 
of  RIP as pre-treatment, or as a preventive measure. It is 
in this setting that RIP has shown greater clinical benefit 
in human trials.
ACUTE PANCREATITIS
AP is one of  the most common emergency department 
admission gastrointestinal diagnoses in the world, with 
increasing incidences of  up to 30 cases per 100000 popu-
lation, with an overall mortality of  around 2%[73]. Many 
etiologies account for AP, but gallstones and alcohol 
constitute for nearly 70% of  cases. Irrespective of  cause, 
a common pathogenesis seems to involve pancreatic 
hyperstimulation, enzyme (including trypsin) activity up-
regulation in acinar cells and enzyme reflux, leading to 
auto-digestion of  the gland and local inflammation[74,75]. 
Although the full details of  these pathogenic processes 
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remain unknown, an intense local and systemic inflam-
matory response is characteristic of  AP and accounts for 
most aspects of  disease severity, systemic complications 
and clinical outcomes. Treatment is mostly supportive, 
and no specific pharmacologic treatment is currently 
available.
Unsurprisingly, many of  the inflammatory mecha-
nisms I have discussed in previous sections again turn out 
to play essential roles in the pathophysiology of  AP. NF-
KappaB is upregulated in AP, leading to the activation 
of  many inflammatory genes and the upregulation of  
various pro-inflammatory mediators[76]. Monocytes form 
patients with AP show impaired NF-KappaB and STAT3 
regulation[77]. The STAT signal transducers also promote 
the expression of  TNF-α, IL-1 and IL-6 in acute pancre-
atitis[78]. Human and experimental studies have confirmed 
the central role of  these pro-inflammatory cytokines in 
the regulation and perpetuation of  a systemic inflamma-
tory response in AP[79]. Experimental inhibition of  these 
molecules leads to attenuation of  the severity AP, and 
their serum levels have even been useful as predictors of  
severity in the clinical setting.
Interactions between pro-inflammatory cytokines 
and oxidative stress occurs in the development of  the 
inflammatory response in AP, activating common signal 
transduction pathways that lead to amplification of  the 
inflammatory cascade such as NF-KappaB[80]. Increased 
oxidative stress, lipid peroxidation and production of  free 
radicals are important steps in the development of  pan-
creatic tissue injury during AP[80,81]. HO-1 is upregulated 
in pancreatic tissue after experimental AP, contributing to 
intercellular defenses against increased oxidative stress[82], 
and neutrophils and monocytes derived from patients 
with AP have shown to be primed for HO-1 produc-
tion, suggesting that HO-1 upregulation could be a viable 
therapeutic target[83]. Hsp’s and TLRs also participate 
in an interplay between pancreas tissues and etiological 
agents, modulating the local and systemic inflammatory 
cascade[84,85]. Although the role of  NO in the pathophysi-
ology of  AP remains controversial, it can regulate many 
molecular targets and crucial steps of  the inflammatory 
response[86].
Despite advances in the understanding of  these pro-
cesses, there is no evidence of  a clinical benefit of  anti-
oxidant or anti-cytokine therapies in AP. We have already 
seen that both IP and RIP modulate all of  these mecha-
nisms in general, but particular evidence concerning the 
pancreas is available. Pancreatic IP is effective in reducing 
the severity of  IR-induced pancreatitis, partly through 
the modulation of  IL-1 signaling[87-89]. IP also reduces the 
severity of  caerulein-induced pancreatitis and can also ac-
celerate pancreatic repair, also partly through a reduction 
of  the inflammatory process and induction of  hsp70[28,90]. 
IP can also preserve microcirculation, reduce neutrophil 
infiltration and necrosis after IR-induced pancreatitis[91]. 
Some of  these findings have been extended to RIP. RIP 
via hepatic IP also reduced the severity of  IR-induced 
pancreatitis, in part through reduced IL-1 production[92], 
but these findings could not be replicated by renal RIP[93].
Considering that a systemic inflammatory response is 
the hallmark of  severe acute pancreatitis and its associ-
ated systemic complications, RIP again emerges as an in-
triguing therapeutic possibility (Table 1). Its wide-ranging 
immunomodulatory effects, including those that target 
essential pathways known to participate in the physiopa-
thology of  AP, could turn out to be beneficial. Preven-
tion of  systemic complications and subsequent repair 
could also be achieved by RIP. RIP could also be specially 
effective in post-endoscopic retrograde cholangiopan-
creatography pancreatitis, as a periprocedural preventive 
measure. 
CONCLUSION
The clinical application of  RIP is an active field of  re-
search. It is a safe, tolerable and simple procedure, with 
wide-ranging immunomodulatory effects. Most clini-
cal studies concern the utility of  RIP in preventing IR-
injury in the setting of  vascular surgery or myocardial 
infarction, but at least one study has found a beneficial 
effect of  RIP in reducing a non-ischemic injury, that of  
contrast nephropathy[31]. Recent developments also sug-
gest that gastrointestinal protection via RIP might be 
clinically effective. Serum from human subjects subject-
ed to RIP was able to protect human cultured intestinal 
cells from hypoxia-induced damage[94]. And in a recent 
randomized control trial, RIP was shown to protect the 
intestine against IR-injury associated to open abdominal 
aneurism repair, as evidenced by decreased levels of  in-
testinal injury markers such as serum intestinal fatty acid-
binding protein, endotoxin levels and diamine oxidase 
activity[95].
Considering that the protective effects of  RIP are 
thought to depend on its modulation of  the inflammato-
ry response and oxidative status, its therapeutic potential 
could be expanded to other non-ischemic inflammatory 
conditions. I have shown that inflammatory gastrointes-
tinal conditions such as IBD, RE, AP and drug-induced 
hepatotoxicity could be ideal candidates for RIP treat-
ment, considering that their pathophysiological pro-
cesses mirror to an extent those of  IR-injury, and have 
themselves been shown to be modulated by RIP. RIP is 
most often thought of  as a preventive strategy, since it 
is usually applied before the development of  injury or 
disease. This makes RE and post-endoscopic retrograde 
colangiopancreatography pancreatitis the most logical 
candidates. However, the immunomodulatory effects of  
ischemic conditioning are known to persist even after 
an initial ischemic injury is established, a phenomenon 
known as ischemic post-conditioning[96]. Of  course, clini-
cal applicability would have to be determined following 
extensive pre-clinical experimentation and appropriate 
clinical trials. Precise timing, preconditioning technique 
and route would have to be determined as well. However, 
the current evidence suggests RIP has a great potential in 
treating these and other pathologic conditions. 
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